Traders Circulating Word Pluristem's Treatment For Graft Failure, Incomplete Hematopoietic Recovery Received Orphan Drug Designation From FDA; Pluristem Shares Spiked To After-Hours High Of $1.46, Now Up ~3.8% To $1.35
Benzinga Newsdesk